

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/694,432
Filing Date	October 27, 2003
Confirmation Number	8934
First Named Inventor	Kathleen C.M. Campbell
Group Art Unit	8934 1614
Examiner Name	Rebecca Cook LESUEA R. RYAN
Attorney Docket No.	SIU 7399

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
LAR	98	4,961,926		Gabrilove	10-09-1990
LAR	99	5,667,791		Hersh et al.	09-16-1997
LAR	100	6,265,386		Campbell	07-24-2001

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
LAR	101	WO	98/14182	A1	Southern Illinois University	04-09-1998	
LAR	102	WO	03/045334	A2	Sound Pharmaceuticals Inc.	06-05-2003	

Examiner
Signature

Date
Considered

21 FEBRUARY 2006


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/694,432
				Filing Date	October 27, 2003
				Confirmation Number	8934
				First Named Inventor	Kathleen C.M. Campbell
				Group Art Unit	8934-1614
				Examiner Name	Rebecca Cook LESUEA ROUNDS
Sheet	2	of	2	Attorney Docket No.	SIU 7399


OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
WAR	103	GENTILE-RAMOS, Treatment of Diaper Erythema with Methionine" Archivos De Pediatria Del Uruguay, Vol. 36, No. 8 (8/1965) pp. 519-528.	
WAR	104	Partial International Search for analogous Application No. PCT/US2004/035626 dated June 28, 2005.	

Examiner Signature		Date Considered	21 FEBRUARY 2006
--------------------	---	-----------------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 			Application Number	10/694,432
			Filing Date	October 27, 2003
			Confirmation Number	not yet assigned
			First Named Inventor	Campbell
			Group Art Unit	not yet assigned 1614
Sheet 1	of 8	Attorney Docket No. SIU 7399		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	2,732,400		Weiss	01-24-1956
	2	4,426,372		Borch	01-17-1984
	3	5,002,755		Mitchell et al.	03-26-1991
	4	5,292,773		Hirsch et al.	03-08-1994
	5	5,430,064		Hirsch et al.	07-04-1995
	6	5,466,678		Kawabata et al.	11-14-1995
	7	6,177,434		Kopke et al.	01-23-2001

ALREADY CITED AND CONSIDERED - see IDS 03/04/05

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
LPE	8	EP	06 200 04	A1	Fuji Kagaku Kogyo Kabushiki Kaisha	10-19-1994	

Examiner Signature		Date Considered	01 FEB 06
--------------------	---	-----------------	-----------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/694,432
		Filing Date	October 27, 2003
		Confirmation Number	not yet assigned
		First Named Inventor	Campbell
		Group Art Unit	not yet assigned 1614
Sheet	8	of	Attorney Docket No. SIU 7399

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	9	ALDEN, W. WESLEY et al., "Exacerbation of Cisplatin-Induced Nephrotoxicity by Methionine," <u>Chem.-Biol. Interactions</u> , 1984, 48, Pgs. 121-124	
	10	BASINGER, MARK A. et al., "Dithiocarbamate-Induced Biliary Platinum Excretion and the Control of cis-Platinum Nephrotoxicity," <u>Toxicology and Applied Pharmacology</u> , 1988, 97, Pgs. 279-288	
	11	BASINGER, MARK A. et al., "L-Methionine Antagonism of cis-Platinum Nephrotoxicity," <u>Toxicology and Applied Pharmacology</u> , 1990, 108, Pgs. 1-15	
	12	BASINGER, MARK A. et al., "L-Methionine Suppresses Pathological Sequelae of cis-Platinum in the Rat," <u>Fundamental and Applied Toxicology</u> , 1990, 14, Pgs. 568-577	
	13	BOOGAARD, PIETER J. et al., "4-Methylthiobenzoic Acid Reduces Cisplatin Nephrotoxicity In Rats Without Compromising Anti-Tumor Activity," <u>Biochemical Pharmacology</u> , 1991, Vol. 41, No. 12, Pgs. 1997-2003	
	14	BOOGAARD, PIETER J. et al., "The Role of Methallothionein in the Reduction of Cisplatin-Induced Nephrotoxicity by Bi ³⁺ -Pretreatment in the Rat <i>In Vivo</i> and <i>In Vitro</i> , Are Antioxidant Properties of Methallothionein More Relevant than Platinum Binding?", <u>Biochemical Pharmacology</u> , 1991, Vol. 41, No. 3, Pgs. 368-375	
	15	BURCHENAL, JOSEPH H. et al., "Studies of Cross-Resistance, Synergistic Combinations and Blocking of Activity of Platinum Derivates," <u>Biochimie</u> , 1978, 60, No. 9, Pgs. 961-965	
	16	CAMPBELL, KATHLEEN C.M. et al., "A Review of Cisplatin Protective Agents Emphasizing Nephro- and Otoprotectants," <u>Proposed Review Article Not Yet Submitted for Publication, Including Additional Reference Lists</u>	
	17	CAMPBELL, KATHLEEN C.M. et al., "D-Methionine Provides Excellent Protection from Cisplatin Ototoxicity in the Rat," <u>Hearing Research</u> , 1996, 102, Pgs. 90-98	

Examiner Signature		Date Considered	11 FEBRUARY 2004
--------------------	---	-----------------	------------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/694,432
		Filing Date	October 27, 2003
		Confirmation Number	not yet assigned
		First Named Inventor	Campbell
		Group Art Unit	not yet assigned 1614
Sheet	3 of 8	Attorney Docket No.	SIU 7399

	18	CAMPBELL, KATHLEEN C.M. et al., "D-Methionine Provides Protection Against Cisplatin Damage the Rat Stria Vascularis: A Semi-Quantitative Analysis," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 537, Pgs. 135	
	19	CARDINI, G. et al., "La Radioprotezione Dei Cromosomi Delle Cellule Midollari Umane In Vitro," <u>Radiobiologia Radioterapia E Fisica Medica</u> , 1967, Vol. 22, No. 6, Pgs. 371-375	
	20	CARRITHERS, S. L. et al., "Methylation Of Radiation Protector Compounds By Thiol Methyltransferase," <u>FASEB</u> , 1991, Vol. 5, No. 4, Pg. A824	
	21	CHURCH, MICHAEL W. et al., "The Comparative Effects of Sodium Thiosulfate, Diethyldithiocarbamate, Fosfomycin and WR-2721 on Ameliorating Cisplatin-Induced Ototoxicity," <u>Hearing Research</u> , 1995, 86/1,2, Pgs. 195-203	
LAL	22	CORREA, J. N. et al., "Radiosensitization and radioprotection on murine chondrosarcoma," <u>Radiation Research</u> , 1978, Vol. 74, No. 3, Pg. 517	
	23	DE VECCHI, A., "Sperimentazione Clinica Di Una Nuova Sostanza Radioprotettiva (Cloruro Di Metil-Metionin-Sulfonio)," <u>Radiobiologia Radioterapia E Fisica Medica</u> , 1967, Vol. 22, No. 5, Pgs. 355-370	
	24	DEDON, PETER C. et al., "Characterization of the Reactions of Platinum Antitumor Agents with Biologic and Nonbiologic Sulfur-Containing Nucleophiles," <u>Biochemical Pharmacology</u> , 1987, Vol. 36, No. 12, Pgs. 1955-1964	
	25	DEEGAN, PATRICIA M. et al., "The nephrotoxicity, cytotoxicity and renal handling of a cisplatin-methionine complex in male Wistar rats," <u>Toxicology</u> , 1994, 89, Pgs. 1-14	
	26	DREWINKO, B. et al., "The Effect of <i>cis</i> -Diamminedichloroplatinum(II) on Cultured Human Lymphoma Cells and Its Therapeutic Implications," <u>Cancer Research</u> , December 1973, 33, Pgs. 3091-3095	
	27	DROBNIK, JAROSLAV et al., "Inactivation Of Bacteriophages With <i>Cis</i> -Platinum(II) Diamminedichloride," <u>Chem.-Biol. Interactions</u> , 1975, Pgs. 365-375	
	28	FRIEDMAN, M. E. et al., "The Blocking Of The Tetrachloroplatinate(II) Inhibition Of Malate Dehydrogenase By Sulfur-Containing Amino Acids," <u>Biochimica et Biophysica Acta</u> , 1974, 341, Pgs. 277-283	

Examiner Signature		Date Considered	2 FEBRUARY 2006
--------------------	---	-----------------	-----------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/694,432	
		Filing Date	October 27, 2003	
		Confirmation Number	not yet assigned	
		First Named Inventor	Campbell	
		Group Art Unit	not yet assigned 1614	
Sheet	of	8	Attorney Docket No.	SIU 7399

	29	FRIEDMAN, MENDEL et al., "The Utilization and Safety of Isomeric Sulfur-Containing Amino Acids in Mice," <u>J. Nutr.</u> , 1984, 114, Pgs. 2301-2310	
	30	GABAIZADEH, RAMIN et al., "Protection of Both Auditory Hair Cells and Auditory Neurons from Cisplatin Induced Damage," <u>Acta Otolaryngol</u> (Stockholm), 1997, 117, Pgs. 232-238	
	31	GANDARA, DAVID R. et al., "Cisplatin Chemoprotection and Rescue: Pharmacologic Modulation of Toxicity," <u>Seminars in Oncology</u> , February 1991, Vol. 18, No. 1, Suppl. 3, Pgs. 49-55	
ALREADY CITED AND CONSIDERED - see IDS 03/04/05	32	GANDARA, DAVID R. et al., "Evaluation of Cisplatin Dose Intensity: Current Status and Future Prospects," <u>Anticancer Research</u> , 1989, 9, Pgs. 1121-1128	
	33	GESSLER, N. et al., "Antiradiation effects of S-methylmethionine (Vitamin U)," <u>Prikl. Biokhim. Mikrobiol.</u> , 1996, Vol. 32, No. 6, Pgs. 666-668	
LAR	34	GLOVER, DONNA et al., "Clinical Trials of WR-2721 and Cis-Platinum," <u>I. J. Radiation Oncology, Biology, Physics</u> , May 1989, Vol. 16, No. 5, Pgs. 1201-1204	
LAR	35	HANNERMAN, JORG et al., "Cisplatin-Induced Lipid Peroxidation and Decrease of Gluconeogenesis in Rat Kidney Cortex: Different Effects of Antioxidants and Radical Scavengers," <u>Toxicology</u> , 1988, 51, Pgs. 119-132	
LAR	36	HAYES, D. et al., "Amelioration Of Renal Toxicity Of High Dose Cis-Platinum Diammine Dichloride (CPDD) By Mannitol Induced Diuresis," <u>Proc. Am. Assoc. Cancer Res.</u> , 1976	
LAR	37	INFANTE, G. A. et al., "Chemical radioprotection on biological important compounds," <u>Radiation Research</u> , 1976, Vol. 67, No. 3, Pg. 637	
	38	JONES, MARK M. et al., "Coadministration of Dimethyl Sulfoxide Reduces Cisplatin Nephrotoxicity," <u>Anticancer Research</u> , 1991, 11, Pgs. 1939-1942	
	39	JONES, MARK M. et al., "Control of Nephrotoxicity in the Rat during Repeated cis-Platinum Treatments," <u>Journal of Applied Toxicology</u> , 1989, Vol. 9(4), Pgs. 229-233	
ALREADY CITED AND CONSIDERED - see IDS 03/04/05	40	JONES, MARK M. et al., "Control of the Nephrotoxicity of Cisplatin by Clinically Used Sulfur-Containing Compounds," <u>Fundamental and Applied Toxicology</u> , 1992, 18, Pgs. 181-188	
		JONES, MARK M. et al., "Inhibition of cis-diamminedichloroplatinum (II)-induced renal toxicity in the rat," <u>Cancer Chemotherapy and Pharmacology</u> , 1986, 17, Pgs. 38-42	

Examiner Signature		Date Considered	21 FEBRUARY 2006
--------------------	---	-----------------	------------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/694,432
				Filing Date	October 27, 2003
				Confirmation Number	not yet assigned
				First Named Inventor	Campbell
				Group Art Unit	not yet assigned 1614
Sheet	5	of	8	Attorney Docket No.	SIU 7399

	42	JONES, MARK M. et al., "Relative effectiveness of some compounds for the control of cisplatin-induced nephrotoxicity," <u>Toxicology</u> , 1991, 68: Pgs. 227-247	
	43	JONES, MARK M. et al., "Thioether Suppression of Cisplatin Nephrotoxicity in the Rat," <u>Anticancer Research</u> , 1991, 11, Pgs. 449-454	
	44	JONES, MARK M. et al., "Thiol and Thioether Suppression of Cis-Platinum-Induced Nephrotoxicity in Rats Bearing the Walker 256 Carcinosarcoma," <u>Anticancer Research</u> , 1989, 9: 1937-1942	
	45	KIDO, K., "The influence of methylmethionine sulfonium chloride (MMSC) on survivors of mice after X-ray irradiation, especially the consideration of the drug effect for the degeneration of intestinal mucosa," <u>Kansai Ika Daigaku Zasshi</u> , 1973, Vol. 25, No. 1, Pgs. 104-107	
	46	KIES, CONSTANCE et al., "Comparative Value of L-, DL-, and D-Methionine Supplementation of an Oat-based Diet for Humans," <u>J. Nutr.</u> , 1975, 105, Pgs. 809-814	
	47	KOPKE, RICHARD D. et al., "Use of Organotypic Cultures of Corti's Organ to Study the Protective Effects of Antioxidant Molecules on Cisplatin-Induced Damage of Auditory Hair Cells," <u>The American Journal of Otology</u> , 1997, 18, 559-571	
	48	KORVER, K. D. et al., "Round window application of D-methionine provides cisplatin otoprotection," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 536, Pg. 135	
	49	KOVACS, V. et al., "Study of the Radiation Protection Effect of Selenium-Methionine by Determining the Paramagnetic Properties of Liver Tissues of Mice," 1988, <u>Acta Physica Hungarica</u> , Vol. 64, No. 1-3, Pgs. 321-326	
ALREADY CITED AND CONSIDERED SEE IDS 03/04/05	50	MEKHTIEV, M. A. et al., "Radioprotective effect during the separate and combined use of DL-methionine and thyroxine," <u>Database Chemabs: Chemical Abstracts Service</u> , Abstract No. 76:54431, 1970 (see also <u>Tr. Inst. Fiziol., Akad. Nauk Azerb. SSR</u> , Vol. 11, pp. 83-100, 1970)	
	51	MELVIK, JAN EGIL et al., "Reduction of cis-Dichlorodiammineplatinum-Induced Cell Inactivation by Methionine," <u>Inorganica Chimica Acta</u> , 1987, 137, Pgs. 115-118	
	52	MERRIN, CLAUDE, "A New Method To Prevent Toxicity With High Doses Of Cis Diammine Platinum (Therapeutic Efficacy In Previously Treated Widespread And Recurrent Testicular Tumors)," <u>Proc. Am. Assoc. Cancer Res.</u> , 1976	

Examiner Signature		Date Considered	21 FEBRUARY 2006
--------------------	---	-----------------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/694,432		
		Filing Date	October 27, 2003		
		Confirmation Number	not yet assigned		
		First Named Inventor	Campbell		
		Group Art Unit	not yet assigned 1614		
Sheet	6	of	8	Attorney Docket No.	SIU 7399

	53	MOLTENI, F. et al., "The use of S-adenosyl-methionine as a radioprotective agent," <u>Gazetta Medica Italiana</u> , 1978, Vol. 137, No. 7-8, Pgs 303-308	
	54	MONTINE, THOMAS J. et al., "Role of Endogenous Sulfur-Containing Nucleophiles in an In Vitro Model of cis-Diamminedichloroplatinum(II)-Induced Nephrotoxicity," <u>Biochemical Pharmacology</u> , 1990, Vol. 39, No. 11, Pgs. 1751-1757	
	55	NAKANO, SACHIKO et al., "Potentiation of Cisplatin-Induced Lipid Peroxidation in Kidney Cortical Slices by Glutathione Depletion," <u>Japan. J. Pharmacol.</u> , 1989, 50, Pgs. 87-92	
	56	ORMOND, T. et al., "Reduced Nephrotoxicity In Vivo and In Vitro of Cisplatin-Methionine Complex," <u>Brit. J. Pharmacol. (suppl.)</u> , 1988, 95, Pg. 584P	
	57	PRINTEN, KENNETH J. et al., "Utilization of D-methionine during total parenteral nutrition in postsurgical patients," <u>The American Journal of Clinical Nutrition</u> , June 1979, 32, Pgs. 1200-1205	
	58	RAVI, RADHIKA P. et al., "Relationship of Pharmacodynamic Effects of Cisplatin to the Glutathione Levels in Cochlea, Inferior Colliculus and Kidney," <u>Pharmacologist</u> , 1991, 33(3), D-19, 402, P. 217	
	59	RAVI, RADHIKA P. et al., "Diethyldithiocarbamate Protects Against Cisplatin Ototoxicity and Nephrotoxicity," <u>Otolaryngology Head and Neck Surgery</u> , 1992, 107(2), Poster 5, P. 232	
	60	RESER, D. H. et al., "Physiological evidence for protection from cis-platin ototoxicity by D- and L-methionine in vivo," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 203, P. 51	
	61	RHO, M. B. et al., "Structural evidence for protection from cisplatin ototoxicity by both D- and L-methionine in vivo," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 202, P. 51	
	62	ROMITO, S., "Sulla radioprotezione cromosomica in vitro: esperienze con metionina, acido aspartico, leucina, lisina," <u>Fracastoro</u> , 1969, Vol. 62, No. 6, Pgs. 576-581	
	63	SALIKHODZHAEV, Z. et al., "Stimulation of postirradiation recovery of rat haemopoiesis by a cobalt preparation," <u>Database Biosis Biosciences Information Service</u> , Philadelphia, Pennsylvania, Abstract No. 08095385 (see also <u>Radiobiologia</u> , Vol. 31, No. 6, pp. 835-837, 1991)	
	64	SCHEIN, P. S., "Ethyol™ (WR-2721): a chemoprotective agent for platinum anti-cancer drugs," <u>Speaker Abstracts (XP-002053095)</u>	

Examiner Signature	Date Considered	21 FEBRUARY 2004
--------------------	-----------------	------------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/694,432		
		Filing Date	October 27, 2003		
		Confirmation Number	not yet assigned		
		First Named Inventor	Campbell		
		Group Art Unit	not yet assigned 1614		
Sheet	8	of	8	Attorney Docket No.	SIU 7399

ALREADY CITED - SEE IDS 0310/105		SCHWEITZER, VANESSA GAYL, "Cisplatin-Induced Ototoxicity: The Effect of Pigmentation and Inhibitory Agents," <u>Laryngoscope</u> , April 1993, 103, Pgs. 1-52	
LAR	66	SHA et al., "Antioxidant therapy attenuates gentamicin-induced ototoxicity," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 535, P. 134	
	67	SPEER, R. J. et al., "Coordination Complexes of Platinum as Antitumor Agents," <u>Cancer Chemotherapy Reports</u> , 1975, Part I, Vol. 59, No. 3, Pgs. 629-641	
	68	SRINIVASAN, V. et al., "Radioprotection By Misoprostol (PGE ₁ Methyl Analog) In Combination With Vitamin E, Selenomethionine and WR-3689794," <u>Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 2</u> , edited by K. V. Honn et al., 1997, Plenum Press, New York, Pgs. 791-797	
	69	TOGNELLA, SERGIO, "Pharmacological interventions to reduce platinum-induced toxicity," <u>Cancer Treatment Reviews</u> , 1990, 17, Pgs. 139-142	
	70	TRESKES, MARCO et al., "WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach," <u>Cancer Chemotherapy and Pharmacology</u> , 1993, 33, Pgs. 93-106	
	71	VAN DE WATER, T. et al., "Oxidative stress in the inner ear: Combinatorial therapy;" (202) M. B. Rho et al., "Structural evidence for protection from cisplatin ototoxicity by both D- and L-methionine in vivo," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 6, P. 2	
	72	WALKER, ERNEST M., JR. et al., "Methods of Reduction of Cisplatin Nephrotoxicity," <u>Annals of Clinical and Laboratory Science</u> , 1981, Vol. 11, No. 5, Pgs. 397-409	
ALREADY CITED AND CONSIDERED - SEE IDS 0310/105		WARD, J. M. et al., "Modification of the Renal Toxicity of cis-Dichlorodiammineplatinum(II) With Furosemide in Male F344 Rats," <u>Cancer Treatment Reports</u> , 1977, Vol. 61, No. 3, Pgs. 375-379	
	74	WHITWORTH, C. A. et al., "Alpha-lipoic acid as a protective agent against ototoxicity;" (535) S. H. Sha et al., "Antioxidant therapy attenuates gentamicin-induced ototoxicity," <u>Abstracts of the Twenty-First Annual Mid-Winter Research Meeting of the Association for Research in Otolaryngology</u> , February 15-19, 1998, Abstract No. 532, P. 134	

Examiner Signature		Date Considered	21 FEBRUARY 2004
--------------------	---	-----------------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**


(use as many sheets as necessary)

OTPE
NOV 17 2005

Complete if Known			
Application Number		10/694,432	
Filing Date		October 27, 2003	
Confirmation Number		not yet assigned	
First Named Inventor		Campbell	
Group Art Unit		not yet assigned 1614	
Sheet	8	of	8
Attorney Docket No.		SIU 7399	

75	ZEZULKA, ALLISON YATES et al. "Nitrogen Retention in Men Fed Isolated Soybean Protein Supplemented with L-Methionine, D-Methionine, N-Acetyl-L-Methionine, or Inorganic Sulfate," <i>J. Nutr.</i> , 1976, 106, Pgs. 1286-1291	
----	---	--

ALREADY CITED + CONSIDERED - SEE IDS 02/04/05

Examiner Signature 	Date Considered	21 FEBRUARY 2006
--	-----------------	------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.